The study of clinico-pathological correlation and treatment outcome in acute allograft rejection in the immediate post renal transplant period


  • Aadil Beigh Department of Nephrology, Indraprastha Apollo Hospital, New Delhi, India
  • Bheem Raj Gupta Department of Nephrology, Indraprastha Apollo Hospital, New Delhi, India
  • Gaurav Sagar Department of Nephrology, Indraprastha Apollo Hospital, New Delhi, India
  • D. K. Agarwal Department of Nephrology, Indraprastha Apollo Hospital, New Delhi, India



Acute rejection, Immunosuppression, Kidney transplant


Background: The kidney Tx is the treatment of choice for patients with ESRD. However, episodes of AR have a negative impact on short- and long-term graft survival. In spite of immunosuppressive medications, CNI, MMF and steroid, the AR remains a crucial problem for Tx. This analysis was performed to evaluate the changing profile of early AR (during first week of transplant) and its repercussions on graft survival.

Methods: This study was an observational cohort study and included 50 renal transplant patients irrespective of age, sex and race who developed bx proven AR within first week of transplant. Three groups were made according to histopathology: ACR, AMR and mixed rejection group. The patients were followed for 6 months thereafter.

Results: AR within a week of renal Tx were less symptomatic except decrease in UO. ACR was more common (72%) than AMR and mixed rejections. AMR and Mixed group required more therapeutic modalities than ACR. More patients required HD during AR in AMR and mixed rejection group than ACR. The mean at 6 months was 1.3,1.5 and 1.6 in ACR, AMR and mixed group respectively. There were more incidences of BK viremia, CMV infection UTI and rejection fronts follow up in AMR and mixed group than ACR group.

Conclusions: Acute rejections within a week are less symptomatic and ACR occurred more frequently than AMR and mixed rejection There were more incidences of BKV, CMV and UTI for 6 months follow up in AMR and Mixed rejection group.


Annual data report: Atlas of the end stage renal disease in the United States. National institute of health, National institute of diabetes and kidney disease, Bethesda. US renal data system 2002.Accessed at:

Cameron JI, Whiteside C, Katz J, Devins GM. Differences in quality of life across renal replacement therapies: a meta-analytic comparison. Am J Kidney Dis. 2000;35(4):629-37.

Meier‐Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004 r;4(3):378-3.

Sancho Calabuig A. Capdevila Plaza L, Franco Esteve A. Acute rejection and late renal transplant failure: risk factors and prognosis. Nephrol Dial Transplant. 2004;19.

Jane C Tan, Busque S, John D Scalding. Clinical management. Brenner & rector’s the Kidney, 9th Ed.2528-2530.

Tesi RJ, Elkhammas EA, Henry ML, Davies EA, Salazar A, Ferguson RM. Acute rejection episodes: best predictor of long-term primary cadaveric renal transplant survival. In Transplant Proc. 1993;25:901-2.

Pirsch JD, Ploeg RJ, Gange S, D'alessandro AM, Knechtle SJ, Sollinger HW, Kalayoglu M, Belzer FO. Determinants of graft survival after renal transplantation. Transplant. 1996;61(11):1581-6.

Almond PS, Matas A, Gillingham K, Dunn DL, Payne WD, Gores P, et al. Risk factors for chronic rejection in renal allograft recipients. Transplant. 1993;55(4):752-6.

Ferguson R. Acute rejection episodes-best predictor of long-term primary cadaveric renal transplant survival. Clinic Transplant. 1994;8(3):328-31.

Flechner SM, Modlin CS, Serrano DP, Goldfarb DA, Papajcik D, Mastroianni B, et al. Determinants of chronic renal allograft rejection in cyclosporine-treated recipients. Transplant. 1996;62(9):1235-41.

Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a Summary Kidney Int. 2010;77(4):299-311.

Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, et al. Bortezomib provides effective therapy for antibody-and cell-mediated acute rejection. Transplant. 2008;86(12):1754-61.

Mariat C, Alamartine E, Diab N, de Filippis JP, Laurent B, Berthoux F. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients. Transplant Int. 1998;11(3):231-6.

Hamida FB, Barbouch S, Bardi R, Helal I, Kaaroud H, Fatma LB, et al. Acute rejection episodes after kidney transplantation. Saudi J Kidney Dis Transplant. 2009;20(3):370.

Costa R, Malheiro J, Santos C, Fonseca I, La Salete M, Pedroso S, et al. Acute rejection during the first six-months after transplantation: temporal trends regarding risk factors and effects on graft and patient survival. Port J Nephrol Hypert. 2014;28:40-8.

Chung YC, Lee PH, Chang CN, Hu RH, Lee CS. Clinical manifestations of acute rejection in renal allograft recipients receiving cyclosporine-A therapy. J Formos Med.1991;90:375-81.

Sun Q, Liu ZH, Ji S, Chen J, Tang Z, Zeng C, et al. Late and early C4d-positive acute rejection: different clinico-histopathological subentities in renal transplantation. Kidney Int. 2006;70(2):377-83.

Perrella RR, Duerinckx AJ, Tessier FN, Danovitch GM, Wilkinson A, Gonzalez S, et al. Evaluation of renal transplant dysfunction by duplex Doppler sonography: a prospective study and review of the literature. Am J Kidney Dis. 1990;15(6):544-50.

Heilman RL, Nijim S, Chakkera HA, Devarapalli Y, Moss AA, Mulligan DC, et al. Impact of acute rejection on kidney allograft outcomes in recipients on rapid steroid withdrawal. J Transplant. 2011;2011.

Sijpkens YW, Doxiadis II, Mallat MJ, de Fijter JW, Bruijn JA, Claas FH, et al. Early versus late acute rejection episodes in renal transplantation. Transplant. 2003;75(2):204-8.

Opelz G, Döhler B. Influence of time of rejection on long-term graft survival in renal transplantation. Transplant. 2008;85(5):661-6.

Sagedal S, Nordal KP, Hartmann A, Degré M, Holter E, Foss A, et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients1. Transplant. 2000;70(8):1166-74.

Khoury JA, Storch GA, Bohl DL, Schuessler RM, Torrence SM, Lockwood M, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant. 2006;6(9):2134-43.

Hirsch HH, Knowles W, Dickenmann M, Passweg J, Klimkait T, Mihatsch MJ, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. New Eng J Med. 2002;347(7):488-96.

Sachdeva MS, Nada R, Jha V, Sakhuja V, Joshi K. The high incidence of BK polyoma virus infection among renal transplant recipients in India. Transplant. 2004;77(3):429-31.

Vinod PB, Sharma RK, Gupta A, Kaul A. Incidence clinical spectrum and outcome of opportunistic infections in live related renal transplant recipients. Indian J Nephrol. 2007;17(3).

Babu DM, Hase NK, Halankar AR. Study of risk factors for urinary tract infection in renal transplant recipients. Indian J Nephrol. 2007;17(3).




How to Cite

Beigh, A., Gupta, B. R., Sagar, G., & Agarwal, D. K. (2019). The study of clinico-pathological correlation and treatment outcome in acute allograft rejection in the immediate post renal transplant period. International Journal of Research in Medical Sciences, 7(5), 1486–1493.



Original Research Articles